

# *Plasmodium falciparum* *pfhrp2* and *pfhrp3* Gene Deletions and Relatedness to Other Global Isolates, Djibouti, 2019–2020

Eric Rogier,<sup>1</sup> Jessica N. McCaffery,<sup>1</sup> Mohamed Ali Mohamed, Camelia Herman, Doug Nace, Rachel Daniels, Naomi Lucchi, Sophie Jones, Ira Goldman, Michael Aidoo, Qin Cheng, Edie A. Kemenang, Venkatachalam Udhayakumar, Jane Cunningham

Deletions of *pfhrp2* and paralogue *pfhrp3* (*pfhrp2/3*) genes threaten *Plasmodium falciparum* diagnosis by rapid diagnostic test. We examined 1,002 samples from suspected malaria patients in Djibouti City, Djibouti, to investigate *pfhrp2/3* deletions. We performed assays for *Plasmodium* antigen carriage, *pfhrp2/3* genotyping, and sequencing for 7 neutral microsatellites to assess relatedness. By PCR assay, 311 (31.0%) samples tested positive for *P. falciparum* infection, and 296 (95.2%) were successfully genotyped; 37 (12.5%) samples were *pfhrp2+/pfhrp3+*, 51 (17.2%) were *pfhrp2+/pfhrp3-*, 5 (1.7%) were *pfhrp2-/pfhrp3+*, and 203 (68.6%) were *pfhrp2-/pfhrp3-*. Histidine-rich protein 2/3 antigen concentrations were reduced with corresponding gene deletions. Djibouti *P. falciparum* is closely related to Ethiopia and Eritrea parasites (pairwise  $G_{ST}$  0.68 [Ethiopia] and 0.77 [Eritrea]). *P. falciparum* with deletions in *pfhrp2/3* genes were highly prevalent in Djibouti City in 2019–2020; they appear to have arisen de novo within the Horn of Africa and have not been imported.

**D**iagnosis and appropriate case management of *Plasmodium falciparum* infection has greatly improved in many malaria-endemic settings through

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E. Rogier, J.N. McCaffery, C. Herman, D. Nace, N. Lucchi, S. Jones, I. Goldman, M. Aidoo, V. Udhayakumar); Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA (J.N. McCaffery); Hôpital Général Peltier, Djibouti City, Djibouti (M.A. Mohamed); Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA (R. Daniels); Broad Institute, Cambridge, Massachusetts, USA (R. Daniels); Australian Defence Force Malaria and Infectious Disease Institute, Brisbane, Queensland, Australia (Q. Cheng); World Health Organization, Geneva, Switzerland (E.A. Kemenang, J. Cunningham)

the use of rapid diagnostic tests (RDTs) that detect the histidine-rich protein 2 (HRP2) antigen (1). As the only *Plasmodium* species infecting humans to produce this antigen, the *P. falciparum* parasite expresses HRP2 in abundance and releases it into the bloodstream during blood-stage infection, making this marker a very sensitive and specific target for *falciparum* malaria (1,2). The *pfhrp2* gene is located on chromosome 8 of the parasite genome, and a paralogous gene (*pfhrp3*) is located on chromosome 13. The 2 protein products share common epitopes for diagnostic antibodies, enabling the HRP3 antigen to also be detected to some extent by HRP2-based RDTs (3–6).

*P. falciparum* produces large quantities of these antigens during human blood-stage infection, but their biologic functions are not well elucidated, and *pfhrp2*-deleted and *pfhrp3*-deleted parasites still complete the human–mosquito lifecycle successfully (7). Reports of these gene deletions have increased over the past decade from multiple countries in Africa, South America, and Asia (<https://apps.who.int/malaria/maps/threats>) (8). For countries that rely on HRP2-based RDTs for diagnosis of *P. falciparum* infection, those reports affirm the need to monitor the performance of this tool because deleted parasites could emerge and elicit false-negative results.

*P. falciparum* infection represents ≈99.7% of all malaria cases in sub-Saharan Africa, and ≈300 million HRP2-based RDTs are used in this region annually (9). Studies in the east Africa countries of Eritrea (10) and Ethiopia (11,12) have found high prevalence of *pfhrp2/pfhrp3* deletions, forcing changes away from HRP2-based RDTs to accurately diagnose *P. falciparum*.

*parum* infections in these countries. Furthermore, it is unknown whether these deleted genotypes are a result of importation and expansion or whether de novo deletions are arising from local *P. falciparum* lineages. A recent report from Djibouti, which borders both Eritrea and Ethiopia, investigated 79 *P. falciparum*-infected patients and found ≈80% of parasites were lacking both *pfhrp2* and *pfhrp3* genes (13). Triggered by health workers' reports of false-negative RDT results, we report data from an investigation of 1,002 suspected malaria patients enrolled in Djibouti City during December 2019–March 2020. Data were generated for infection-causing *Plasmodium* species, *pfhrp2/3* genotype, concordance with laboratory antigen detection, and relatedness to other global *P. falciparum* parasites.

## Materials and Methods

### Patient Enrollment and Ethics Statement

This activity was considered by the Ministry of Health of Djibouti, the World Health Organization (WHO) Ethical Review Committee, and Centers for Disease Control and Prevention (CDC) human subjects office as nonresearch and as public health surveillance (0900f3eb81abbef6). In December 2020, a study was initiated to investigate presence of *pfhrp2/3* deletions in Djibouti because of 4 specimens that tested negative by HRP2-based RDT (CareStart Malaria Combo RDT; Access Bio, <https://access-bio.net>) but were positive for *P. falciparum* lactate dehydrogenase (pf-LDH) (Bioline Malaria Ag Pf [HRP2/pLDH] Test; Abbott, <https://www.abbott.com>) and also confirmed for *P. falciparum* infection by microscopy. During January 29–March 11, 2020, consecutive patients of varying ages experiencing symptoms of malaria who sought care at Général Peltier Hospital, Djibouti City, were tested by malaria RDT with the First Response Malaria Ag (pLDH/HRP2) Combo Card Test (Premier Medical Corporation, <https://www.premiermedcorp.com>) and routine venipuncture for hematologic and electrolyte profiling.

### Dried Blood Spot Creation

Dried blood spots (DBS) were prepared from remaining venous blood with 50–75 µL of remnant in EDTA tubes spotted on Whatman Protein Saver cards 903 or Whatmann 3M filter paper (Cytiva Life Sciences, <https://www.cytivalifesciences.com>). The spots were dried for ≥4 hours at room temperature and then stored with desiccant in sealable bags and shipped to the CDC (Atlanta, GA, USA).

### *Plasmodium* Antigen Detection by Laboratory Multiplex Assay

DBS processing and testing for *Plasmodium* antigens were performed at CDC as described previously (14,15). A 6-mm punch was taken from each DBS for elution in blocking buffer (final whole blood dilution of 1:20) for the bead-based multiplex antigen detection assay of pan-*Plasmodium* aldolase and lactate dehydrogenase (LDH), HRP2 (and HRP3), and *P. vivax* LDH (PvLDH). Assay plates were run on a MAGPIX machine (Luminex Corp., <https://www.luminex-corp.com>) with a target of 50 beads per region.

### *Plasmodium* Species Identification by PCR and *pfhrp2* and *pfhrp3* Genotyping

We selected DBS samples positive for any *Plasmodium* antigens for DNA extraction (DNA Mini Kit; QIAGEN, <https://www.qiagen.com>) and *Plasmodium* species-specific photo-induced electron transfer (PET) PCR and quantification of DNA (16). Samples positive for *P. falciparum* DNA had nested PCR reactions for single-copy *pfmsp1* and *pfmsp2* genes as quality control for DNA quantity and integrity (17,18). We further assayed only those samples amplifying both control genes to determine presence or absence of *pfhrp2* and *pfhrp3* genes. Genotyping for *pfhrp2* was performed by a single-step PCR amplifying *pfhrp2* inclusive of both exons (19), and genotyping for *pfhrp3* was through 2 nested PCR reactions with primers specific for exon 1–2 and exon 2 regions (17,18). All genotyping reactions were run by 2 independent operators on different days and by a third operator if amplification results were discordant.

### Genetic Haplotypes through Neutral Microsatellites

To assess multiplicity of infection and relatedness of *P. falciparum* parasites, we selected 7 neutral microsatellite (NMS) genetic markers: TA1 on chromosome 6, poly-α on chromosome 4, PfPK2 on chromosome 12, 2490 on chromosome 10, C2M34–313 on chromosome 2, C3M69–383 on chromosome 3, and TA109 on chromosome 6 (10,20). We determined the sizes of the amplification products by capillary electrophoresis on an Applied Biosystems 3130xl Genetic Analyzer (ThermoFisher Scientific, <https://www.thermofisher.com>) and analyzed data by using GeneMarker version 3.0.0 (SoftGenetics, <https://softgenetics.com>). We considered infections monoclonal if all 7 NMS had only 1 allele call. We used NMS data from previous studies to compare Djibouti results to *P. falciparum* parasites from other countries (Appendix Table 1, <https://wwwnc.cdc.gov/EID/article/28/10/22-0695-App1.pdf>).

**Statistical Analysis**

We compared lognormal means for HRP2/3 antigen concentration by genotype by using the 2-tailed Student *t* test with equal variance. For secondary analyses, we divided antigen assay signals for the entire sample set into low and high HRP2/3 antigen levels by comparing them with levels of the pLDH and pAldolase antigens as described previously (21). In brief, if blood samples were positive for pan-*Plasmodium* LDH or aldolase and negative for HRP2/3 antigens or had atypically low amounts of HRP2/3 relative to the pan-*Plasmodium* targets, we selected them as high-priority specimens with phenotypic evidence for *pfhrp2/3* gene deletions (Appendix Figure 1).


We assessed NMS data and measures of relatedness by using the PopGenReport package in R (R Foundation for Statistical Computing, <https://www.r-project.org>) (22). For all countries, we used monoclonal infections and polyclonal infections with distinct haplotypes or dominant haplotypes for the relatedness and principal component analysis.

**Results**

During January 29–March 20, 2020, of the suspected malaria cases registered at Général Peltier Hospital, 998 DBS were collected; an additional 4 samples previously collected in December 2019 were included in the sample set because they were identified as highly suspicious of *pfhrp2/3* deletions on the basis of RDT results (Figure 1). Laboratory antigen screening revealed 630 (62.9%) samples were negative for all antigens; those samples were not investigated further because there was no suspicion of *Plasmodium* spp. infection.

We extracted DNA from the remaining 372 (37.1%) *Plasmodium* antigen-positive samples for further molecular investigation. Of those 372 samples, detectable *Plasmodium* DNA was absent in 17 (4.6%) samples, and 44 samples (11.8%) were found to be *P. vivax* single-species infections; samples within these 2 groups were not considered further for *pfhrp2/3* deletion reporting. Of the remaining 311 samples containing *P. falciparum* DNA, 15 (4.8%) did not amplify both *pfmsp1* and *pfmsp2* single-copy genes and were not eligible for reporting of *pfhrp2/3* genotypes. Of the 296 *P. falciparum* infections that qualified for reporting genotyping, 37 (12.5%) were a genotype of *pfhrp2+/pfhrp3+*, 51 (17.2%) were *pfhrp2+/pfhrp3-*, 5 (1.7%) were *pfhrp2-/pfhrp3+*, and 203 (68.6%) were a double-deletion genotype of *pfhrp2-/pfhrp3-* (Figure 1). For all 296 samples of *P. falciparum* infections successfully genotyped, 208 (70.3%) demonstrated a *P. falciparum* infection with *pfhrp2* deletion and 254 (85.8%) showed deletion in the *pfhrp3* gene.

Using the hypothetical selection method (see Methods) based on levels of pan-*Plasmodium* antigens compared with HRP2/3 antigens, of the 372 antigen-positive samples, 241 (64.8%) had a complete absence of HRP2/3 assay signal, 20 (5.4%) had an atypically low amount of HRP2/3 relative to other pan-*Plasmodium* antigens, and 111 (29.8%) had high levels of HRP2/3 relative to other pan-*Plasmodium* antigens (Appendix Figure 1). Of all 241 samples negative for HRP2/3 signal, 183 (75.9%) were appropriate for *pfhrp2/3* genotyping, and all demonstrated a *pfhrp2* deletion. When categorized into the low HRP2/3 category, of the 18 samples that qualified for genotyping, 6 (33.3%) showed a deletion of the *pfhrp2* gene. If categorized into the high HRP2/3 category, of 90 samples that qualified for genotyping, the *pfhrp2* gene was amplified in most (74 [82.2%]).



**Figure 1.** Flow diagram for reporting *pfhrp2* and *pfhrp3* genotype for all specimens in study of *Plasmodium falciparum* parasites with *pfhrp2* and *pfhrp3* deletions, Djibouti, 2019–2020. Terminal boxes display number of samples successfully genotyped for *pfhrp2/3*.



We found that concentrations of the HRP2 antigen (with potential supplemented signal from HRP3) were strongly associated with the different *pfhrp2/3* genotypes (Figure 2). With the exception of 1 specimen, all samples found to be positive for the *pfhrp2* gene ( $n = 88$ ) showed high concentrations of the HRP2/3 antigen; the *pfhrp2+*/*pfhrp3+* genotype samples showed a log-normal mean concentration of 10,794 pg/mL, and the *pfhrp2+*/*pfhrp3-* genotype samples showed a log-normal mean concentration of 18,017 pg/mL (Figure 2, panel A). Blood samples from infections with *P. falciparum* parasites lacking the *pfhrp2* gene showed, on average, much lower concentrations of HRP2/3 antigens: log-normal mean of 421 pg/mL in *pfhrp2-*/*pfhrp3+* samples and log-normal mean of 2.0 pg/mL in *pfhrp2-*/*pfhrp3-* samples. Concentration was significantly lower in the blood samples from *pfhrp2-*/*pfhrp3-* parasite infections than in *pfhrp2+*/*pfhrp3+* ( $p < 0.001$ ), *pfhrp2+*/*pfhrp3-* ( $p < 0.001$ ), and *pfhrp2-*/*pfhrp3+* ( $p = 0.049$ ) parasite infections. Of the 5 infections with *pfhrp2-*/*pfhrp3+* parasites, 2 (40.0%) showed an absence of HRP2/3 antigen signal, compared with 185/203 (91.1%) of *pfhrp2-*/*pfhrp3-* infections. Density plots of HRP2/3 antigen concentration by infecting parasite genotype illustrate these trends by genotype category (Figure 2, panel B).


In total, 65 of the Djibouti infections were chosen for NGS sequencing: 20 *pfhrp2+*/*pfhrp3+*, 20 *pfhrp2+*/*pfhrp3-*, 5 *pfhrp2-*/*pfhrp3+*, and 20 *pfhrp2-*/*pfhrp3-*. Of those, 52/65 (80.0%) were found to be monoclonal infections, and this finding did not differ significantly by genotype: *pfhrp2+*/*pfhrp3+* (16/20 [80.0%]), *pfhrp2+*/*pfhrp3-* (15/20 [75.0%]), *pfhrp2-*/*pfhrp3+* (4/5 [80.0%]), *pfhrp2-*/*pfhrp3-* (17/20 [85.5%]). Three of the genotypes (all except for *pfhrp2-*/*pfhrp3+*) showed a high degree of independent clustering by principal component analysis (Figure 3). Both the Jost pairwise D and Hendricks pairwise  $G_{ST}$  measures of gene differentiation found the *pfhrp2-*/*pfhrp3-* genotype to be most related to *pfhrp2-*/*pfhrp3+* parasites (Appendix Table 2).

Comparing relatedness of *P. falciparum* by country (regardless of *pfhrp2/3* genotype) found distinct clustering by the area of the world in which the parasites originated (Figure 4, panel A). Both Jost pairwise D and Hendricks pairwise  $G_{ST}$  found parasites from Djibouti and other parts of Africa more related to each other than to isolates from South America or Asia (Appendix Table 3, Figure 2). When repeating the analysis with only parasites from Africa, Djibouti and Ethiopia parasites were found to be most related in comparison with *P. falciparum* from the other 5 African countries (Appendix Figure 3). For global isolates with *pfhrp2* deletions, South America and Africa parasites were not strongly related to each other; Peru and Suriname parasites had the highest principal component 1 values as well as highest Jost pairwise D and Hendricks pairwise  $G_{ST}$  in comparison with African *pfhrp2*-deleted parasites (Table; Figure 4, panel B). The *pfhrp2* deleted parasites from Sudan, Eritrea, Ethiopia, and Djibouti showed relatively similar principal component 1 values, and Ethiopia and Djibouti *pfhrp2*-deleted genotypes demonstrated the closest overall clustering. Among these deleted parasites, Djibouti *P. falciparum* was most closely related to Ethiopia (pairwise  $G_{ST}$  0.68) *pfhrp2*-deleted *P. falciparum*, followed by Eritrea (0.77), Sudan (0.97), Peru (0.98), and Suriname (0.99). If assessing relatedness among parasites lacking only the *pfhrp3* gene, we noted similar findings; the highest degree of relatedness was seen among the Djibouti and Ethiopia parasites (Appendix Figure 4).

## Discussion

Confirmatory diagnosis of *P. falciparum* malaria through testing for the presence of HRP2 antigen by RDT has been a substantial improvement for providing appropriate case management in many malaria-endemic countries. Discovery of *pfhrp2* gene deletions in natural *P. falciparum* populations has led to doubts


**Figure 2.** Distributions of HRP2/HRP3 antigen concentrations by *pfhrp2* and *pfhrp3* genotype for specimens in study of *Plasmodium falciparum* parasites with *pfhrp2* and *pfhrp3* deletions, Djibouti 2019–2020. A) Individual antigen concentrations for all 296 samples successfully genotyped for *pfhrp2/3*. Dashed line denotes the assay level of quantitation. B) Smoothed kernel density plots for log-transformed HRP2/3 concentration by the four *pfhrp2/3* genotypes. HRP2/3, histidine-rich protein 2/3.



about the sustained use of this antigen for diagnostic purposes (1). To date, most *P. falciparum*-endemic settings that rely heavily on RDTs for routine diagnostics have been found to have populations of parasites that express high amounts of HRP2 and HRP3 antigens (8,15,18,21,23,24). The ability to evade HRP2-based diagnostics (and subsequent treatment) might lead to a selective advantage for parasites with gene deletions (25). Routine surveillance of *P. falciparum*-endemic populations is required to ensure that primary diagnostic tools are still accurate.


Multiple recent studies in the Horn of Africa have demonstrated a high proportion of *P. falciparum* in the region with *pfhrp2* gene deletions and that most isolates also have *pfhrp3* deletions. A 2016 Eritrea health facility survey found 62.0% of *P. falciparum* infections consisted of parasites with both *pfhrp2* and *pfhrp3* deletions, all of which were also HRP2-negative by RDT (10). Of persons enrolled in health facility surveys during 2017–2018 in northern Ethiopia, *pfhrp2* deletions were responsible for between 11.5%–14.9% of false-negative HRP2-RDT results (12). A survey of 3 health facilities in Djibouti in early 2019 also found these concerning results: in a small sample set of 79 *P. falciparum* PCR-positive patients, 86.5% demonstrated *pfhrp2/3* deletions (13).

In light of previous findings, this 2019–2020 study was designed to assess the prevalence of *pfhrp2/3* deletions in Djibouti City, relatedness of Djibouti *P. falciparum* to other global isolates, and overall relatedness of *P. falciparum* within the Horn of Africa compared with other global sites. Most (63%) of the 1,002 DBS samples collected from persons with ma-



**Figure 3.** Relatedness of *Plasmodium falciparum* parasites from Djibouti, 2019–2020, with different *pfhrp2* and *pfhrp3* genotypes. Cluster PC analysis shown for 7 neutral microsatellite data for monogenomic infections by subpopulations: *pfhrp2+*/*pfhrp3+* (n = 16), *pfhrp2+*/*pfhrp3-* (n = 15), *pfhrp2-*/*pfhrp3+* (n = 4), *pfhrp2-*/*pfhrp3-* (n = 17). Plot shown with PC1 on x-axis and PC2 on y-axis with 95% confidence ellipses. PC, principal component.

laria-like symptoms were negative for any *Plasmodium* antigens and did not undergo molecular assays because *Plasmodium* infection was not suspected. The bead-based antigen assay has been shown to detect *Plasmodium* infection at approximately the same level as standard PCR assays at  $\approx 2$  parasites/uL blood (15). Among the remaining 372 *Plasmodium*-positive samples, only 111 (29.8%) displayed moderate to high levels of HRP2/3 antigen profile indicative of *P. falciparum* with functional *pfhrp2* or *pfhrp3* genes. By those *Plasmodium* antigen data alone, the pervasiveness of low or absent HRP2 levels in 70% of samples from symptomatic *Plasmodium*-infected persons raised sus-



**Figure 4.** Relatedness of *Plasmodium falciparum* parasites from Djibouti, 2019–2020 with other global isolates. A) Cluster PC analysis shown for neutral microsatellite data for monogenomic infections by collection from different countries: Angola (n = 32), Costa Rica (n = 14), Djibouti (n = 52), Eritrea (n = 187), Ethiopia (n = 20), Guyana (n = 27), Haiti (n = 86), Peru (n = 18), Rwanda (n = 42), Sudan (n = 37), Suriname (n = 44), Uganda (n = 25). B) Cluster PC analysis shown for neutral microsatellite data for monogenomic infections containing *pfhrp2* deletions by collection from different countries: Djibouti (n = 21), Eritrea (n = 43), Peru (n = 18), Ethiopia (n = 8), Sudan (n = 4), and Suriname (n = 1). Plots shown with PC1 on x-axis and PC2 on y-axis and 95% confidence ellipses. PC, principal component.

RESEARCH

**Table.** Genetic relatedness of *pfhrp2*-deleted *Plasmodium falciparum* parasites from Djibouti, 2019–2020, compared with those from other countries\*

Comparison	Country	Djibouti	Eritrea	Ethiopia	Peru	Sudan
Jost D pairwise	Djibouti					
	Eritrea	0.530				
	Ethiopia	0.444	0.704			
	Peru	0.873	0.888	0.846		
	Sudan	0.920	0.817	0.879	0.994	
	Suriname	0.987	0.831	1.00	0.795	0.962
Hendrick pairwise $G_{ST}$	Djibouti					
	Eritrea	0.772				
	Ethiopia	0.679	0.843			
	Peru	0.977	0.972	0.953		
	Sudan	0.972	0.917	0.941	0.999	
	Suriname	0.998	0.949	1.000	0.991	0.990

\*Darker shading indicates higher level of relatedness.

picion of either a high frequency of non-*P. falciparum* infections or high prevalence of *P. falciparum* isolates with the *pfhrp2/3* genes deleted; both scenarios were found to be true in Djibouti. Of the 355 samples with detectable *Plasmodium* DNA by PET-PCR, 44 (12.4%) were single-species *P. vivax* infections; this finding is in line with previous reports of *P. vivax* in Djibouti, as well as in neighboring Ethiopia and Eritrea (9,26). Most (95%) of the 311 samples with *P. falciparum* DNA were successfully genotyped for single-copy control genes (17), reflecting high-density infections in the symptomatic study population. Of the 296 *P. falciparum* infections with reportable genotyping results, only 37 (12.5%) contained wild-type parasites with both *pfhrp2* and *pfhrp3* genes amplified. Only *pfhrp3* was deleted in 17.2% of parasites, only *pfhrp2* was deleted in 1.7%, and more than two thirds of all infections (68.6%) were from *P. falciparum* lacking both genes. The 68.6% prevalence of double-deleted parasites in Djibouti City is lower than the 86.5% previously reported by Iriart et al. (13). This high prevalence of *pfhrp2/3* dual-deleted infections, coupled with our finding that most infections are monoclonal (80%), suggests that a high percentage of *P. falciparum* infections in Djibouti City would not be detected by HRP2-based RDTs. This level is well beyond the 5% threshold recommended by the WHO to consider a replacement of exclusive HRP2-based diagnostics for detecting *P. falciparum* (27), and the findings from our study have already been shared with the Djibouti Ministry of Health and WHO regional partners.

Regarding relatedness to other global isolates, the parasites found in Djibouti (regardless of genotype) clustered closely with *P. falciparum* haplotypes from Africa and showed greater distance to *P. falciparum* from the New World and Asia. Djibouti City is a large port city located on the east central coast and is home to approximately half the country’s population. Because Djibouti City is a large center of trade and

population movement, some enrolled patients might have contracted *P. falciparum* infection in a country other than Djibouti, but travel history for participants was unavailable for this study. However, the objective genetic data show that even if some infections were acquired outside Djibouti, they all appear to be Africa-derived from more proximal countries. High relatedness (low diversity) of *P. falciparum* within Djibouti has been previously observed for isolates collected throughout the country within individual surveys and without substantial differences among multiple years of collection (28), although genotyping for *pfhrp2/3* deletions was not performed. The relatedness of Djibouti and Ethiopia *pfhrp2*-deleted parasites observed in this study was closer when compared with Eritrea or Sudan isolates and very distant from *pfhrp2*-deleted *P. falciparum* from Peru and Suriname. The same finding was noted for *pfhrp3*-only deleted parasites, where Djibouti and Ethiopia populations practically overlie each other. This evidence points to de novo gene deletions and expansion of these deleted *P. falciparum* populations in the Horn of Africa rather than importation of deleted parasites from other areas of the world. Specifically for the Horn of Africa, close background lineages by NMS data for *pfhrp2*- and *pfhrp3*-deleted parasites from Djibouti and Ethiopia points to an expansion of common gene-deleted populations that exist in these adjacent countries. Eritrea parasite lineages from both wild-type and deleted *P. falciparum* appear to be differentiated from the Ethiopia/Djibouti lines, suggesting separate *pfhrp2/3* deletion events on unique *P. falciparum* strains and a more distant common ancestor.

This study and its findings are subject to limitations. Though many patients exhibiting malaria symptoms were enrolled in Djibouti City, no other areas of the country are represented by this sample set, so these conclusions and estimates could not necessarily be applied nationwide. However, Djibouti



City accounts for 95% of the country's malaria case load and Général Peltier Hospital is the largest hospital in the region, and previous reports have found *P. falciparum* in Djibouti to be of overall low diversity (28,29). Furthermore, the Djibouti Ministry of Health considered these results sufficiently representative to mandate a nationwide RDT policy change. Without the recent travel history of enrolled participants, we cannot state all *P. falciparum* parasites analyzed in this study originated in Djibouti. Quality microscopy could not be performed uniformly on these blood samples, so we were unable to obtain visual confirmation of *P. falciparum*. In addition, because of laboratory workflow, RDT results from enrollment could not be reliably linked with venous blood samples and therefore were not compared directly with laboratory data. However, the 4 samples collected in December 2019 that triggered this investigation demonstrated *pfhrp2/3* deletions causing known false-negative results by HRP2-based RDT.

In conclusion, results from both antigen detection and *pfhrp2/3* molecular genotyping provide evidence of a high prevalence of symptomatic malaria cases in Djibouti caused by *P. falciparum* lacking functional *pfhrp2/3* genes. These findings, coupled with high occurrence of monoclonal infections and single *pfhrp2*-deleted infections, suggest that nearly 70% of HRP2-based RDTs would return negative results for *P. falciparum* infection in Djibouti, which is expected to have serious negative health impacts on the community. Djibouti *P. falciparum* parasites with gene deletions are most closely related to other parasites in the Horn of Africa with a recent common ancestor or routine importation from Ethiopia. Gene-deleted haplotypes show no evidence of importation from South America.

### Acknowledgments

We thank the staff of Général Peltier Hospital and Ghosem Zamani, who greatly assisted with this investigation.

The Bill and Melinda Gates Foundation and Centers for Disease Control and Prevention provided funding for this study.

### About the Author

Dr. Rogier is a microbiologist in the Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention. His laboratory develops multiplex serologic assays for the detection of antibodies and antigens against infectious diseases and works to interpret this serologic data for making assumptions about population-level epidemiology and disease transmission.

### References

- Poti KE, Sullivan DJ, Dondorp AM, Woodrow CJ. HRP2: transforming malaria diagnosis, but with caveats. *Trends Parasitol.* 2020;36:112–26. <https://doi.org/10.1016/j.pt.2019.12.004>
- Rogier E, Hamre KES, Joseph V, Plucinski MM, Presume J, Romilus I, et al. Conventional and high-sensitivity malaria rapid diagnostic test performance in 2 transmission settings: Haiti 2017. *J Infect Dis.* 2020;221:786–95.
- Lee N, Gatton ML, Pelecanos A, Bubb M, Gonzalez I, Bell D, et al. Identification of optimal epitopes for *Plasmodium falciparum* rapid diagnostic tests that target histidine-rich proteins 2 and 3. *J Clin Microbiol.* 2012;50:1397–405. <https://doi.org/10.1128/JCM.06533-11>
- Baker J, Ho MF, Pelecanos A, Gatton M, Chen N, Abdullah S, et al. Global sequence variation in the histidine-rich proteins 2 and 3 of *Plasmodium falciparum*: implications for the performance of malaria rapid diagnostic tests. *Malar J.* 2010;9:129. <https://doi.org/10.1186/1475-2875-9-129>
- World Health Organization. Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 8 (2016–2018). Geneva: The Organization; 2018.
- Kong A, Wilson SA, Ah Y, Nace D, Rogier E, Aidoo M. HRP2 and HRP3 cross-reactivity and implications for HRP2-based RDT use in regions with *Plasmodium falciparum* *hrp2* gene deletions. *Malar J.* 2021;20:207. <https://doi.org/10.1186/s12936-021-03739-6>
- Gambo D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, et al. A large proportion of *P. falciparum* isolates in the Amazon region of Peru lack *pfhrp2* and *pfhrp3*: implications for malaria rapid diagnostic tests. *PLoS One.* 2010;5:e8091. <https://doi.org/10.1371/journal.pone.0008091>
- Thomson R, Parr JB, Cheng Q, Chenet S, Perkins M, Cunningham J. Prevalence of *Plasmodium falciparum* lacking histidine-rich proteins 2 and 3: a systematic review. *Bull World Health Organ.* 2020;98:558–568F. <https://doi.org/10.2471/BLT.20.250621>
- World Health Organization. World malaria report 2019. Geneva: The Organization; 2019.
- Berhane A, Anderson K, Mihreteab S, Gresty K, Rogier E, Mohamed S, et al. Major threat to malaria control programs by *Plasmodium falciparum* lacking histidine-rich protein 2, Eritrea. *Emerg Infect Dis.* 2018;24:462–70. <https://doi.org/10.3201/eid2403.171723>
- Girma S, Cheaveau J, Mohon AN, Marasinghe D, Legese R, Balasingam N, et al. Prevalence and epidemiological characteristics of asymptomatic malaria based on ultrasensitive diagnostics: a cross-sectional study. *Clin Infect Dis.* 2019;69:1003–10. <https://doi.org/10.1093/cid/ciy1005>
- Feleke SM, Reichert EN, Mohammed H, Brhane BG, Mekete K, Mamo H, et al. *Plasmodium falciparum* is evolving to escape malaria rapid diagnostic tests in Ethiopia. *Nat Microbiol.* 2021;6:1289–99. <https://doi.org/10.1038/s41564-021-00962-4>
- Iriart X, Menard S, Chauvin P, Mohamed HS, Charpentier E, Mohamed MA, et al. Misdiagnosis of imported *falciparum* malaria from African areas due to an increased prevalence of *pfhrp2/pfhrp3* gene deletion: the Djibouti case. *Emerg Microbes Infect.* 2020;9:1984–7. <https://doi.org/10.1080/22221751.2020.1815590>
- Rogier E, Nace D, Ljolje D, Lucchi NW, Udhayakumar V, Aidoo M. Capture and Detection of *Plasmodium vivax* Lactate Dehydrogenase in a Bead-Based Multiplex Immunoassay. *Am J Trop Med Hyg.* 2020;102:1064–7. <https://doi.org/10.4269/ajtmh.19-0772>
- Plucinski MM, Herman C, Jones S, Dimbu R, Fortes F, Ljolje D, et al. Screening for *Pfhrp2/3*-deleted *Plasmodium*

- falciparum*, non-falciparum, and low-density malaria infections by a multiplex antigen assay. *J Infect Dis*. 2019;219:437–47. <https://doi.org/10.1093/infdis/jiy525>
16. Lucchi NW, Narayanan J, Karell MA, Xayavong M, Kariuki S, DaSilva AJ, et al. Molecular diagnosis of malaria by photo-induced electron transfer fluorogenic primers: PET-PCR. *PLoS One*. 2013;8:e56677. <https://doi.org/10.1371/journal.pone.0056677>
  17. Abdallah JF, Okoth SA, Fontecha GA, Torres RE, Banegas EI, Matute ML, et al. Prevalence of pfrhp2 and pfrhp3 gene deletions in Puerto Lempira, Honduras. *Malar J*. 2015;14:19. <https://doi.org/10.1186/s12936-014-0537-7>
  18. Bharti PK, Chandel HS, Ahmad A, Krishna S, Udhayakumar V, Singh N. Prevalence of pfrhp2 and/or pfrhp3 gene deletion in *Plasmodium falciparum* population in eight highly endemic states in India. *PLoS One*. 2016;11:e0157949. <https://doi.org/10.1371/journal.pone.0157949>
  19. Jones S, Subramaniam G, Plucinski MM, Patel D, Padilla J, Aidoo M, et al. One-step PCR: a novel protocol for determination of pfrhp2 deletion status in *Plasmodium falciparum*. *PLoS One*. 2020;15:e0236369. <https://doi.org/10.1371/journal.pone.0236369>
  20. Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of *Plasmodium falciparum* kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. *Lancet Infect Dis*. 2021;21:1120–8. [https://doi.org/10.1016/S1473-3099\(21\)00142-0](https://doi.org/10.1016/S1473-3099(21)00142-0)
  21. Bakari C, Jones S, Subramaniam G, Mandara CI, Chiduo MG, Rumisha S, et al. Community-based surveys for *Plasmodium falciparum* pfrhp2 and pfrhp3 gene deletions in selected regions of mainland Tanzania. *Malar J*. 2020;19:391. <https://doi.org/10.1186/s12936-020-03459-3>
  22. Daniels RF, Chenet S, Rogier E, Lucchi N, Herman C, Pierre B, et al. Genetic analysis reveals unique characteristics of *Plasmodium falciparum* parasite populations in Haiti. *Malar J*. 2020;19:379. <https://doi.org/10.1186/s12936-020-03439-7>
  23. Parr JB, Kieta E, Phanzu F, Mansiangi P, Mwandagaliwa K, Mvuama N, et al. Analysis of false-negative rapid diagnostic tests for symptomatic malaria in the Democratic Republic of the Congo. *Sci Rep*. 2021;11:6495. <https://doi.org/10.1038/s41598-021-85913-z>
  24. Herman C, Huber CS, Jones S, Steinhardt L, Plucinski MM, Lemoine JF, et al. Multiplex malaria antigen detection by bead-based assay and molecular confirmation by PCR shows no evidence of Pfrhp2 and Pfrhp3 deletion in Haiti. *Malar J*. 2019;18:380. <https://doi.org/10.1186/s12936-019-3010-9>
  25. Gattton ML, Dunn J, Chaudhry A, Ciketic S, Cunningham J, Cheng Q. Implications of parasites lacking *Plasmodium falciparum* histidine-rich protein 2 on malaria morbidity and control when rapid diagnostic tests are used for diagnosis. *J Infect Dis*. 2017;215:1156–66. <https://doi.org/10.1093/infdis/jix094>
  26. de Santi VP, Khaireh BA, Chiniard T, Pradines B, Taudon N, Larréché S, et al. Role of *Anopheles stephensi* mosquitoes in malaria outbreak, Djibouti, 2019. *Emerg Infect Dis*. 2021;27:1697–700. <https://doi.org/10.3201/eid2706.204557>
  27. World Health Organization. Response plan to pfrhp2 gene deletions. Geneva: The Organization; 2019.
  28. Khaireh BA, Assefa A, Guessod HH, Basco LK, Khaireh MA, Pascual A, et al. Population genetics analysis during the elimination process of *Plasmodium falciparum* in Djibouti. *Malar J*. 2013;12:201. <https://doi.org/10.1186/1475-2875-12-201>
  29. Rogier C, Pradines B, Bogreau H, Koeck JL, Kamil MA, Mercereau-Puijalon O. Malaria epidemic and drug resistance, Djibouti. *Emerg Infect Dis*. 2005;11:317–21. <https://doi.org/10.3201/eid1102.040108>

---

Address for correspondence: Eric Rogier, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop D67, Atlanta, GA, 30329-4027, USA; email: [erogier@cdc.gov](mailto:erogier@cdc.gov)



# *Plasmodium falciparum* *pfhrp2* and *pfhrp3* Gene Deletions and Relatedness to Other Global Isolates, Djibouti, 2019–2020

## Appendix

**Appendix Table 1.** Source of NMS data from previous studies

Country	Year(s)	Samples with NMS data used in current study (n)	Reference
Angola	2019	32	(1)
Costa Rica	2019	14	(2)
Eritrea	2019	173	(3)
Eritrea	2016	14	(4)
Ethiopia	2018	20	(5)
Guyana	2010	27	(6)
Haiti	2016	86	(7)
Indian Subcontinent†	2013–2016	11	(8)
Malaysia*	2008–2014	27	(9)
Peru	2010–2012	18	(10)
Rwanda	2018	42	(11)
Sudan	2010–2018	37	(12)
Suriname	2013–2014	43	(13)
Uganda	2018	25	(14)

\*NMS, neutral microsatellite.

†Inclusive of India and Pakistan. Did not include complete 7 NMS panel, so used only in supplementary analysis.

**Appendix Table 2.** Jost's D and Hendrick G<sub>st</sub> relatedness of Djibouti *P. falciparum* by *pfhrp2* and *pfhrp3* genotype\*


Comparison	Genotypes	pfhrp2+/pfhrp3+	pfhrp2+/pfhrp3-	pfhrp2-/pfhrp3+	pfhrp2-/pfhrp3-
Jost's D Pairwise	pfhrp2+/pfhrp3+	0.734			
	pfhrp2+/pfhrp3-	0.395	0.475		
	pfhrp2-/pfhrp3+	0.721	0.506	0.346	
	pfhrp2-/pfhrp3-				
Hendrick Pairwise G <sub>st</sub>	pfhrp2+/pfhrp3+	0.924			
	pfhrp2+/pfhrp3-	0.662	0.691		
	pfhrp2-/pfhrp3+	0.948	0.832	0.630	
	pfhrp2-/pfhrp3-				

\*Darker shading indicates higher level of relatedness.

**Appendix Table 3.** Jost's D and Hendrick Gst relatedness of Djibouti *Plasmodium falciparum* compared to *P falciparum* from other countries\*


Comparison	Genotypes	Djibouti	Angola	Costa Rica	Eritrea	Ethiopia	Guyana	Haiti	Peru	Rwanda	Sudan	Suriname
Jost's D Pairwise	Djibouti											
	Angola	0.699										
	Costa Rica	0.924	0.746									
	Eritrea	0.636	0.786	0.977								
	Ethiopia	0.486	0.670	0.894	0.752							
	Guyana	0.949	0.875	0.895	0.985	0.954						
	Haiti	0.657	0.630	0.821	0.882	0.634	0.999					
	Peru	0.926	0.864	0.895	0.970	0.903	0.460	1.00				
	Rwanda	0.586	0.478	0.875	0.724	0.516	0.932	0.519	0.966			
	Sudan	0.772	0.600	0.943	0.756	0.744	0.966	0.731	0.997	0.603		
	Suriname	0.867	0.919	0.917	0.813	0.916	0.514	0.925	0.804	0.905	0.892	
	Uganda	0.598	0.496	0.924	0.791	0.494	0.970	0.474	0.993	0.375	0.633	0.941
	Hendrick Pairwise Gst	Djibouti										
Angola		0.796										
Costa Rica		0.965	0.844									
Eritrea		0.761	0.861	0.990								
Ethiopia		0.610	0.758	0.944	0.835							
Guyana		0.976	0.933	0.957	0.993	0.976						
Haiti		0.803	0.769	0.921	0.941	0.769	1.00					
Peru		0.976	0.948	0.976	0.991	0.963	0.802	1.00				
Rwanda		0.702	0.587	0.928	0.816	0.620	0.964	0.676	0.988			
Sudan		0.849	0.699	0.969	0.838	0.816	0.982	0.839	0.999	0.700		
Suriname		0.927	0.953	0.961	0.895	0.950	0.714	0.966	0.938	0.944	0.936	
Uganda		0.716	0.609	0.958	0.866	0.604	0.985	0.641	0.998	0.486	0.730	0.966

\*Darker shading indicates higher level of relatedness.




**Appendix Figure 1.** Comparison of the HRP2/3 assay signal with other pan-*Plasmodium* antigen targets to categorize sample set into high and low HRP2/3 levels. Scatterplots for HRP2/3 immunoassay signal as compared to pan-*Plasmodium* lactate dehydrogenase (A) or pan-*Plasmodium* aldolase (B) signals. C) Flowchart for genotype reporting for all samples if dichotomizing by HRP2/3 category. For all panels, red shading indicates complete absence of HRP2/3 assay signal, blue shading indicates relatively low HRP2/3 signal when compared with pan-*Plasmodium* targets, and green shading indicates high HRP2/3 signal compared with pan-*Plasmodium* targets.






**Appendix Figure 2.** Relatedness of Djibouti *Plasmodium falciparum* parasites with other global isolates with limited neutral microsatellite data. Inclusion of Asian isolates with only 4 neutral microsatellite targets published (TA1, Poly $\alpha$ , PfPK2, 2490). Plots shown with PC1 on x-axis and PC2 on y-axis, with 95% confidence ellipses



**Appendix Figure 3.** Relatedness of Djibouti *Plasmodium falciparum* parasites with other African isolates. Plots shown with PC1 on x-axis and PC2 on y-axis, with 95% confidence ellipses.



**Appendix Figure 4.** Relatedness of Djibouti *Plasmodium falciparum* parasites with other African isolates lacking only *pfhrp3*. Plots shown with PC1 on x-axis and PC2 on y-axis, with 95% confidence ellipses.

## References

1. Dimbu PR, Horth R, Cândido ALM, Ferreira CM, Caquece F, Garcia LEA, et al. Continued low efficacy of artemether-lumefantrine in Angola in 2019. *Antimicrob Agents Chemother.* 2021;65:e01949-20. [PubMed https://doi.org/10.1128/AAC.01949-20](https://doi.org/10.1128/AAC.01949-20)
2. Santamaría AM, Vásquez V, Rigg C, Moreno D, Romero L, Justo C, et al. *Plasmodium falciparum* genetic diversity in Panamá based on *glurp*, *msp-1* and *msp-2* genes: implications for malaria elimination in Mesoamerica. *Life (Basel).* 2020;10:E319. [PubMed https://doi.org/10.3390/life10120319](https://doi.org/10.3390/life10120319)
3. Mihreteab S, Anderson K, Pasay C, Smith D, Gatton ML, Cunningham J, et al. Epidemiology of mutant *Plasmodium falciparum* parasites lacking histidine-rich protein 2/3 genes in Eritrea 2 years after switching from HRP2-based RDTs. *Sci Rep.* 2021;11:21082. [PubMed https://doi.org/10.1038/s41598-021-00714-8](https://doi.org/10.1038/s41598-021-00714-8)
4. Berhane A, Anderson K, Mihreteab S, Gresty K, Rogier E, Mohamed S, et al. Major threat to malaria control programs by *Plasmodium falciparum* lacking histidine-rich protein 2, Eritrea. *Emerg Infect Dis.* 2018;24:462–70. [PubMed https://doi.org/10.3201/eid2403.171723](https://doi.org/10.3201/eid2403.171723)

5. Leonard CM, Mohammed H, Tadesse M, McCaffery JN, Nace D, Halsey ES, et al. Missed *Plasmodium falciparum* and *Plasmodium vivax* mixed infections in Ethiopia threaten malaria elimination. *Am J Trop Med Hyg.* 2021;106:667–70. [PubMed https://doi.org/10.4269/ajtmh.21-0796](https://doi.org/10.4269/ajtmh.21-0796)
6. Akinyi Okoth S, Abdallah JF, Ceron N, Adhin MR, Chandrabose J, Krishnalall K, et al. Variation in *Plasmodium falciparum* histidine-rich protein 2 (pfhrp2) and *Plasmodium falciparum* histidine-rich protein 3 (pfhrp3) gene deletions in Guyana and Suriname. *PLoS One.* 2015;10:e0126805. [PubMed https://doi.org/10.1371/journal.pone.0126805](https://doi.org/10.1371/journal.pone.0126805)
7. Daniels RF, Chenet S, Rogier E, Lucchi N, Herman C, Pierre B, et al. Genetic analysis reveals unique characteristics of *Plasmodium falciparum* parasite populations in Haiti. *Malar J.* 2020;19:379. [PubMed https://doi.org/10.1186/s12936-020-03439-7](https://doi.org/10.1186/s12936-020-03439-7)
8. Al-Rumhi A, Al-Hashami Z, Al-Hamidhi S, Gadalla A, Naeem R, Ranford-Cartwright L, et al. Influx of diverse, drug resistant and transmissible *Plasmodium falciparum* into a malaria-free setting in Qatar. *BMC Infect Dis.* 2020;20:413. [PubMed https://doi.org/10.1186/s12879-020-05111-6](https://doi.org/10.1186/s12879-020-05111-6)
9. Mohd Abd Razak MR, Sastu UR, Norahmad NA, Abdul-Karim A, Muhammad A, Muniandy PK, et al. Genetic diversity of *Plasmodium falciparum* populations in malaria declining areas of Sabah, East Malaysia. *PLoS One.* 2016;11:e0152415. [PubMed https://doi.org/10.1371/journal.pone.0152415](https://doi.org/10.1371/journal.pone.0152415)
10. Baldeviano GC, Okoth SA, Arrospide N, Gonzalez RV, Sánchez JF, Macedo S, et al. Molecular epidemiology of *Plasmodium falciparum* malaria outbreak, Tumbes, Peru, 2010-2012. *Emerg Infect Dis.* 2015;21:797–803. [PubMed https://doi.org/10.3201/eid2105.141427](https://doi.org/10.3201/eid2105.141427)
11. Uwimana A, Umulisa N, Venkatesan M, Savigel SS, Zhou Z, Munyaneza T, et al. Association of *Plasmodium falciparum* kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. *Lancet Infect Dis.* 2021;21:1120–8. [PubMed https://doi.org/10.1016/S1473-3099\(21\)00142-0](https://doi.org/10.1016/S1473-3099(21)00142-0)
12. Prosser C, Gresty K, Ellis J, Meyer W, Anderson K, Lee R, et al. *Plasmodium falciparum* histidine-rich protein 2 and 3 gene deletions in strains from Nigeria, Sudan, and South Sudan. *Emerg Infect Dis.* 2021;27:471–9. [PubMed https://doi.org/10.3201/eid2702.191410](https://doi.org/10.3201/eid2702.191410)
13. Chenet SM, Okoth SA, Kelley J, Lucchi N, Huber CS, Vreden S, et al. Molecular profile of malaria drug resistance markers of *Plasmodium falciparum* in Suriname. *Antimicrob Agents Chemother.* 2017;61:e02655-16. [PubMed https://doi.org/10.1128/AAC.02655-16](https://doi.org/10.1128/AAC.02655-16)



14. Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated *Plasmodium falciparum* malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. *Malar J.* 2021;20:484. [PubMed](#)  
<https://doi.org/10.1186/s12936-021-04021-5>